{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=7", "query": { "condition": "Ovarian Cancer", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 2464, "total_pages": 247, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T18:40:03.819Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03348631", "title": "Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Endometrial Endometrioid Adenocarcinoma", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Tazemetostat", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 62, "start_date": "2019-05-01", "completion_date": "2027-02-12", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-25T18:40:03.819Z", "location_count": 581, "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 369 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03348631" }, { "nct_id": "NCT02711137", "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB057643", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2016-05-18", "completion_date": "2019-02-13", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-25T18:40:03.819Z", "location_count": 16, "location_summary": "Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711137" }, { "nct_id": "NCT02983799", "title": "Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity" ], "interventions": [ { "name": "OLAPARIB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 272, "start_date": "2016-12-22", "completion_date": "2020-12-03", "has_results": true, "last_update_posted_date": "2022-04-13", "last_synced_at": "2026-10-25T18:40:03.819Z", "location_count": 35, "location_summary": "Anchorage, Alaska • La Jolla, California • Los Angeles, California + 29 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02983799" }, { "nct_id": "NCT04566393", "title": "Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Pancreatic Cancer", "Small Bowel Cancer", "Colorectal Cancer", "Melanoma", "Non Small Cell Lung Cancer", "Thyroid Cancer", "Bladder Cancer", "Head and Neck Cancer", "Gastric Cancer", "Esophageal Cancer", "Cholangiocarcinoma", "Ovarian Cancer", "Hepatocellular Carcinoma", "Glioblastoma", "MAPK Gene Mutation", "KRAS Activating Mutation", "BRAF Gene Mutation", "NRAS Gene Mutation", "HRAS Gene Mutation", "MEK Mutation", "ERK Mutation" ], "interventions": [ { "name": "Ulixertinib (BVD-523)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "xCures", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-25T18:40:03.819Z", "location_count": 26, "location_summary": "Mobile, Alabama • Arroyo Grande, California • Newport Beach, California + 19 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Arroyo Grande", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566393" }, { "nct_id": "NCT03642132", "title": "Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Chemotherapy + avelumab followed by avelumab + talazoparib", "type": "DRUG" }, { "name": "Chemotherapy followed by talazoparib maintenance", "type": "DRUG" }, { "name": "Chemotherapy + bevacizumab followed by bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 79, "start_date": "2018-07-19", "completion_date": "2021-12-22", "has_results": true, "last_update_posted_date": "2023-04-06", "last_synced_at": "2026-10-25T18:40:03.819Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03642132" }, { "nct_id": "NCT03857087", "title": "68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ovarian Carcinoma" ], "interventions": [ { "name": "Gallium Ga 68-labeled PSMA-11", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography (PET)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 7, "start_date": "2018-04-02", "completion_date": "2022-06-30", "has_results": false, "last_update_posted_date": "2022-10-12", "last_synced_at": "2026-10-25T18:40:03.819Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03857087" }, { "nct_id": "NCT05349227", "title": "Comprehensive Outcomes for After Cancer Health", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ovarian Cancer", "Breast Cancer", "Lung Cancer", "Gastric Cancer", "Survivorship", "Endometrial Cancer", "Head and Neck Cancers", "Prostate Cancers", "Geriatric Oncology", "Metastatic Breast Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "Digital Health Coaching Program", "type": "BEHAVIORAL" }, { "name": "Fitbit", "type": "DEVICE" } ], "intervention_types": [ "BEHAVIORAL", "DEVICE" ], "sponsor": "Pack Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 625, "start_date": "2022-06-23", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-10-25T18:40:03.819Z", "location_count": 7, "location_summary": "Gainesville, Florida • Boston, Massachusetts • Omaha, Nebraska + 3 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05349227" }, { "nct_id": "NCT07764328", "title": "This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Balance in Women Who Suffer From Self-reported PCOS Symptoms.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Polycystic Ovarian Syndrome (PCOS)" ], "interventions": [ { "name": "A dietary supplement powder for women", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Mila Mend Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 225, "start_date": "2025-12-23", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-25T18:40:03.819Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07764328" }, { "nct_id": "NCT00408681", "title": "Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, Breakpoint Cluster Region-abl Translocation (BCR-ABL) Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Disseminated Neuroblastoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Gastrointestinal Complications", "Juvenile Myelomonocytic Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Poor Prognosis Metastatic Gestational Trophoblastic Tumor", "Previously Treated Childhood Rhabdomyosarcoma", "Primary Myelofibrosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Splenic Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage III Small Lymphocytic Lymphoma", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Breast Cancer", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Ovarian Epithelial Cancer", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "lithium carbonate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2006-06", "completion_date": "2015-05-01", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-10-25T18:40:03.819Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00408681" }, { "nct_id": "NCT06216561", "title": "Intraperitoneal LSTA1 in CRS-HIPEC", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Ovarian Carcinoma", "Appendix Cancer", "Peritoneal Metastases" ], "interventions": [ { "name": "CRS-HIPEC + LSTA1", "type": "DRUG" }, { "name": "CRS-HIPEC alone", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-11-30", "completion_date": "2024-06-24", "has_results": false, "last_update_posted_date": "2024-08-20", "last_synced_at": "2026-10-25T18:40:03.819Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06216561" } ] }